文献速递癫痫

更换抗癫痫药物生产厂家与癫痫发作风险升高相关:德国全国处方数据研究

Switching the manufacturer of antiepileptic drugs is associated with higher risk of seizures: A nationwide study of prescription data in Germany.
PubMed 文献 · Ann Neurol · 2018-11-08

该研究利用德国IMS疾病分析器数据库2011至2016年的匿名门诊数据,纳入至少360天内有2次、索引日期前180天内有1次抗癫痫药物处方的癫痫患者,按年龄、性别、保险状态和治疗医生1:1匹配癫痫组与无癫痫对照组,分析更换同一抗癫痫药物生产厂家后出现突破性癫痫发作的风险。结果显示癫痫组更换厂家比例高于对照组(26.8% vs 14.2%;OR=1.35,95%CI=1.08-1.69,p=0.009)。作者认为在既往无发作患者中,更换抗癫痫药物生产厂家与癫痫复发风险升高相关。

要点

  • 癫痫组更换抗癫痫药物生产厂家比例高于对照组(26.8% vs 14.2%;OR=1.35,95%CI=1.08-1.69,p=0.009)。
  • 品牌药换为仿制药的比值比OR=1.85(95%CI=1.30-2.64,p<0.001),仿制药之间更换OR=1.45(95%CI=1.13-1.87,p=0.004)。
  • 作者认为在无发作患者中避免更换抗癫痫药物生产厂家是审慎的。

核心结论

  • 在既往无发作的癫痫患者中,更换抗癫痫药物生产厂家与癫痫复发风险升高相关。
  • 作者的回顾性方法无法确定同期其他医疗变化是否促成复发。
  • 作者认为在无发作患者中避免更换抗惊厥药物生产厂家是审慎的。

研究设计与样本

  • 研究使用德国IMS疾病分析器数据库(QuintilesIMS,法兰克福,德国)收集2011年至2016年全德国执业神经科医生的匿名患者数据。
  • 纳入标准为至少360天内有2次处方且索引日期前180天内有1次处方的癫痫患者。
  • 队列分为癫痫组和无癫痫对照组,两组按年龄、性别、保险状态和治疗医生1:1匹配。
  • 采用多变量回归模型分析更换同一抗癫痫药物生产厂家后突破性癫痫发作的风险。

主要发现

  • 共纳入3530例癫痫患者,每组n=1765,年龄=53.7±19.8岁。
  • 癫痫组更换药物生产厂家比例高于对照组(26.8% vs 14.2%;OR=1.35,95%CI=1.08-1.69,p=0.009)。
  • 品牌药换为仿制药的比例癫痫组高于对照组(5.5% vs 2.4%;OR=1.85,95%CI=1.30-2.64,p<0.001)。
  • 仿制药之间更换的比例癫痫组高于对照组(14.7% vs 7.1%;OR=1.45,95%CI=1.13-1.87,p=0.004)。

临床怎么用

  • 作者认为在无发作患者中避免更换抗惊厥药物生产厂家是审慎的。

局限性

  • 作者的回顾性方法无法确定同期其他医疗变化是否促成癫痫复发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Despite bioequivalence, the exchangeability of antiepileptic drugs in clinical settings is disputed. Therefore, we investigated the risk for recurrent seizures after switching the manufacturer of the same drug in a large German cohort. METHODS: Anonymous patient data from practice neurologists throughout Germany between 2011 and 2016 were collected using the IMS Disease Analyzer database (QuintilesIMS, Frankfurt, Germany). People with epilepsy were included if at least 2 prescriptions within 360 days and 1 within 180 days prior to the index date were available. The cohort was separated into a seizure group and seizure-free controls. Both groups were matched 1:1 according to age, gender, insurance status, and treating physician. The risk for breakthrough seizures after a manufacturer switch of the same antiepileptic drug was analyzed using multivariate regression models. RESULTS: A total of 3,530 people with epilepsy were included (each group, n = 1,765; age = 53.7 ± 19.8 years). Patients with seizures had switched the drug manufacturer more often than controls (26.8% vs 14.2%; odds ratio [OR] = 1.35, 95% confidence interval [CI] = 1.08-1.69, p = 0.009), both from branded to generic (5.5% vs 2.4%; OR = 1.85, 95% CI = 1.30-2.64, p < 0.001) and between generic drugs (14.7% vs 7.1%; OR = 1.45, 95% CI = 1.13-1.87, p = 0.004). INTERPRETATION: In previously seizure-free patients, switching the manufacturer of antiepileptic medications was associated with a higher risk for seizure recurrence. Our retrospective approach does not allow us to determine whether other changes in medical care at the same time could contribute to the recurrence. However, it would be prudent to avoid switching the manufacturer of anticonvulsants in seizure-free patients. Ann Neurol 2018;84:918-925.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Lang JD, Kostev K, Onugoren MD, et al. Switching the manufacturer of antiepileptic drugs is associated with higher risk of seizures: A nationwide study of prescription data in Germany. Ann Neurol. 2018. PMID: 30298621. doi:10.1002/ana.25353

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。